Back to News
Market Impact: 0.5

Why Is Donaldson (DCI) Down 0.1% Since Last Earnings Report?

DCIHIMS
Corporate EarningsCompany FundamentalsCorporate Guidance & OutlookAnalyst EstimatesCapital Returns (Dividends / Buybacks)Market Technicals & FlowsAnalyst InsightsTax & Tariffs
Why Is Donaldson (DCI) Down 0.1% Since Last Earnings Report?

Donaldson (DCI) reported fiscal fourth-quarter 2025 adjusted earnings of $1.03 per share and revenues of $981 million, both exceeding Zacks Consensus Estimates by $0.01 and $27 million respectively, with revenue growing 4.8% year-over-year. Despite the beat, the stock has underperformed, losing 0.1% since the report, influenced by a 130 basis point gross margin decline due to tariff-related inflation and a 15% decrease in operating cash flow. For fiscal 2026, DCI forecasts adjusted EPS in the range of $3.92-$4.08 and sales growth of 1-5%, suggesting continued top-line expansion despite margin pressures.

Analysis

Donaldson (DCI) delivered a mixed performance in its fourth-quarter fiscal 2025 results, characterized by a top-line beat but underlying margin and cash flow weakness that explains the stock's anemic performance. The company surpassed consensus estimates with a 4.8% year-over-year revenue increase to $981 million and a 9.6% rise in adjusted EPS to $1.03. Growth was geographically uneven, with strong sales in Europe (+12.3%) but weakness in Latin America (-0.7%), and segment-wise, the high-growth Life Sciences segment (+14%) and solid Industrial Solutions (+8%) were offset by a significant 20% decline in the On-Road business within its largest Mobile Solutions segment. The primary concern for investors is the 130 basis point contraction in gross margin to 34.5%, which the company attributed directly to tariff-related inflation and inventory valuation headwinds. This profitability pressure, coupled with a 15% year-over-year decrease in operating cash flow and a 16.1% drop in free cash flow for the full fiscal year, overshadows the revenue beat. While the fiscal 2026 outlook projects continued growth with sales up 1-5% and adjusted EPS guided to $3.92-$4.08, the forecast for the recently high-flying Life Sciences segment is a deceleration to low single-digit growth, and analyst estimates have flatlined, reflecting a cautious consensus.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.